複合化療市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、給藥途徑、癌症類型、分銷管道、地區和競爭格局分類，2021-2031年

全球複合化療市場預計將從 2025 年的 53.1 億美元成長到 2031 年的 72.1 億美元，複合年成長率為 5.23%。

該市場正從標準化的固定劑量治療方法轉向在無菌環境下研發個人化抗癌藥物，根據每位癌症患者的生理參數，精準自訂其獨特的劑量和製劑需求。這一成長主要受全球癌症發病率上升以及臨床上對精準醫療日益成長的需求所驅動，精準醫療需要客製化的治療方案以實現最佳療效和毒性控制。此外，人口老化對靈活劑量調整的需求不斷成長，也顯著推動了市場需求。

市場促進因素

全球癌症發生率和盛行率的上升是推動複合化療市場成長的根本動力。隨著癌症負擔的加重，臨床上對抗腫瘤治療的需求激增，而商業性的大規模生產卻無法始終滿足這項需求。複合藥局在提供個人化解決方案方面發揮著至關重要的作用，尤其對於需要根據體表面積和特殊配方進行精確劑量調整的患者而言更是如此。根據世界衛生組織（WHO）2025年2月發布的報告，癌症仍是全球主要死因之一，每年奪走約1,000萬人的生命，凸顯了許多病患對靈活便捷的化療方案的需求。同時，市售化療藥物的長期短缺顯著增加了對外包和專業複方藥房的依賴。當傳統藥品供應鏈中斷時，醫院會依賴503B複方藥局來取得Cisplatin和Carboplatin等必需藥物，以確保病患的持續治療。根據賓州大學醫學院2024年12月的數據，在供應中斷高峰期，某些化療藥物的處方率下降了15.1%，凸顯了非處方藥供應的不穩定性，並推動了能夠填補這些短缺的配藥公司的顯著成長。 Fagron公司截至2025年3月的會計年度年度報告顯示，其息稅折舊攤銷前利潤（EBITDA）成長了17%，這直接歸功於其配藥服務的強勁需求，而持續的藥品短缺也為其提供了支撐。

市場挑戰

供應鏈不穩定，尤其是原料和無菌注射劑的供應問題，對化療產業的擴張構成重大障礙。配製機構高度依賴特定抗腫瘤藥物的穩定供應來配製個人化治療方法。當全球製造業重組或關鍵活性藥物成分（API）生產設施的品管問題導致生產中斷時，配藥師會立即面臨庫存短缺。無法取得這些基礎藥物會導致營運停滯，使配製機構無法提供其核心價值提案——精準的劑量調整，最終削弱配製模式的核心優勢。持續的短缺直接限制了市場容量和收入潛力。例如，歐洲醫院藥劑師協會（EAHP）報告稱，到2025年下半年，近64%的受訪醫院藥劑師表示，由於藥物短缺，患者治療被延誤，其中抗癌藥物受影響最為嚴重。這種不確定性迫使醫療機構重新評估資源分配，或轉而採用標準固定劑量方案以維持治療的連續性。因此，無法確保可靠且持續的供應，損害了時間緊迫的癌症治療所需的可靠性和一致性，從而限制了市場成長。

市場趨勢

配藥機器人的廣泛應用正在從根本上改變這一領域，它提高了無菌配藥的精確度，並顯著降低了醫護人員接觸有害抗腫瘤藥物的風險。醫院和專科藥房正擴大採用自動化工作流程，以最大限度地減少複雜劑量計算中的人為錯誤，並在受控環境中安全地控制細胞毒性風險。這項技術變革的基礎是先進檢驗系統的日益普及。美國系統藥劑師協會 (ASHP) 在 2024 年 5 月報告稱，62.8% 的醫院正在使用支援無菌配藥的技術，這凸顯了向自動化安全規程的顯著轉變。同時，居家化療輸液服務市場也經歷了顯著成長，這主要得益於以患者為中心的護理模式的轉變，這種模式優先考慮便利性並旨在降低住院成本。這一趨勢減輕了繁忙的腫瘤中心的運作負擔，並使免疫功能低下的患者能夠在低風險的家庭環境中接受必要的治療。對遠距護理服務日益成長的需求也體現在領先供應商的財務表現中。例如，Option Care Health 報告稱，2024 會計年度淨銷售額成長了 16.2%，這一成長歸功於家庭和替代機構中靜脈輸液療法的使用增加。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球複合化療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依藥物類型（細胞毒性藥物、荷爾蒙、免疫調節劑、分子標靶藥物、支持性治療藥物）
  • 給藥途徑（靜脈注射、口服、皮下注射、肌肉注射、鞘內注射）
  • 癌症類型（乳癌、肺癌、大腸癌、攝護腺癌、白血病、淋巴瘤）
  • 分銷通路（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美複合化療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲複合化療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區複合化療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲複合化療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲複合化療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球複合化療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Pfizer Inc.
• Baxter International Inc.
• Grifols SA
• Comecer SPA
• Arxium Inc.
• Dedalus Group
• B. Braun Melsungen AG
• Omnicell Technologies Inc.
• The Metrix Company
• Sterline SRL

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Compounding Chemotherapy Market is set to expand from USD 5.31 Billion in 2025 to USD 7.21 Billion by 2031, demonstrating a 5.23% CAGR. This market focuses on creating personalized antineoplastic medications in sterile environments, precisely tailored to individual cancer patients' unique dosing and formulation needs based on their physiological parameters, moving beyond standardized fixed-dose regimens. Growth is primarily driven by the increasing global cancer incidence and a rising clinical preference for precision medicine, which demands customized therapeutic protocols for optimal efficacy and toxicity management. Furthermore, the growing geriatric population's need for flexible dosage adjustments significantly sustains market demand.

Market Driver

The expanding global incidence and prevalence of cancer serve as a fundamental catalyst for the growth of the compounding chemotherapy market. As the demographic burden of oncological diseases intensifies, there's a corresponding surge in the clinical demand for antineoplastic treatments that commercial mass production cannot always meet. Compounding pharmacies play a critical role in providing tailored solutions, especially for patients requiring precise dosage adjustments based on body surface area or specialized formulations. According to the World Health Organization in February 2025, cancer remains a leading global cause of death, accounting for nearly 10 million fatalities, underscoring the vast patient volume requiring flexible and accessible chemotherapy options. Concurrently, persistent shortages of commercially available chemotherapy drugs significantly increase reliance on outsourcing and specialized compounders. When conventional pharmaceutical supply chains encounter disruptions, hospitals turn to 503B compounding facilities for essential medications, such as cisplatin and carboplatin, to ensure continuous patient care. Data from Penn Medicine in December 2024 revealed that prescription rates for specific chemotherapy agents dropped by 15.1% during peak supply disruptions, highlighting the volatility of commercial access and driving substantial growth for compounding entities capable of mitigating these shortfalls. Fagron's March 2025 Annual Report noted a 17% increase in REBITDA, directly attributing this growth to robust demand for their compounding services, bolstered by ongoing drug shortages.

Market Challenge

Supply chain instability, particularly concerning raw materials and sterile injectables, represents a significant hurdle for the expansion of the compounding chemotherapy sector. Compounding facilities heavily depend on a consistent flow of specific antineoplastic agents to prepare personalized regimens. When global manufacturing consolidates or quality control issues interrupt production at major active pharmaceutical ingredient (API) facilities, compounding pharmacists face immediate inventory deficits. This inability to procure base ingredients leads to operational slowdowns, hindering facilities from delivering the precise dosage adjustments that constitute their primary value proposition, thereby undermining the core advantage of the compounding model. The persistence of these shortages directly limits market throughput and revenue potential; for instance, the European Association of Hospital Pharmacists reported in late 2025 that nearly 64% of surveyed hospital pharmacists experienced patient therapy delays due to medicine shortages, with oncology drugs being among the most frequently affected. Such unpredictability forces healthcare providers to ration care or revert to standard fixed-dose alternatives to maintain treatment continuity. Consequently, the market's growth is constrained as the inability to ensure a reliable and continuous supply compromises the trust and consistency vital for time-sensitive cancer treatments.

Market Trends

The widespread adoption of robotic compounding automation is fundamentally transforming the sector by enhancing the precision of sterile preparations and significantly reducing healthcare worker exposure to hazardous antineoplastic agents. Hospitals and specialized pharmacies are increasingly integrating automated workflows to minimize human error in complex volumetric calculations and to safely contain cytotoxicity risks within controlled environments. This technological shift is evidenced by the growing penetration of advanced verification systems, with the American Society of Health-System Pharmacists reporting in May 2024 that technologies assisting sterile product preparation are utilized in 62.8% of hospitals, highlighting the critical transition toward automated safety protocols. Simultaneously, the market is experiencing substantial growth in home-based chemotherapy infusion services, driven by a shift towards patient-centric care models that prioritize convenience and aim to reduce hospitalization costs. This trend alleviates the logistical burden on busy oncology centers and allows immunocompromised patients to receive essential treatments in lower-risk home environments. The escalating demand for these remote care capabilities is reflected in the financial performance of major providers; for example, Option Care Health reported a 16.2% net revenue increase for the full year 2024, attributing this surge to the expanded utilization of home and alternate site infusion therapies.

Key Market Players

• Pfizer Inc.
• Baxter International Inc.
• Grifols SA
• Comecer S.P.A.
• Arxium Inc.
• Dedalus Group
• B. Braun Melsungen AG
• Omnicell Technologies Inc.
• The Metrix Company
• Sterline S.R.L

Report Scope

In this report, the Global Compounding Chemotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Compounding Chemotherapy Market, By Drug Type

• Cytotoxic Drugs
• Hormonal Agents
• Immunomodulatory Agents
• Targeted Therapies
• Supportive Care Drugs

Compounding Chemotherapy Market, By Route of Administration

• Intravenous
• Oral
• Subcutaneous
• Intramuscular
• Intrathecal

Compounding Chemotherapy Market, By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Lymphoma

Compounding Chemotherapy Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Compounding Chemotherapy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Compounding Chemotherapy Market.

Available Customizations:

Global Compounding Chemotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Compounding Chemotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs)
  • 5.2.2. By Route of Administration (Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal)
  • 5.2.3. By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Compounding Chemotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Cancer Type
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Compounding Chemotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Cancer Type
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Compounding Chemotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Cancer Type
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Compounding Chemotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Cancer Type
      • 6.3.3.2.4. By Distribution Channel

7. Europe Compounding Chemotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Cancer Type
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Compounding Chemotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Cancer Type
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Compounding Chemotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Cancer Type
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Compounding Chemotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Cancer Type
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Compounding Chemotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Cancer Type
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Compounding Chemotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Cancer Type
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Compounding Chemotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Cancer Type
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Compounding Chemotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Cancer Type
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Compounding Chemotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Cancer Type
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Compounding Chemotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Cancer Type
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Compounding Chemotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Cancer Type
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Compounding Chemotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Cancer Type
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Compounding Chemotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Cancer Type
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Compounding Chemotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Cancer Type
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Compounding Chemotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Cancer Type
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Compounding Chemotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Cancer Type
      • 9.3.3.2.4. By Distribution Channel

10. South America Compounding Chemotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Cancer Type
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Compounding Chemotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Cancer Type
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Compounding Chemotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Cancer Type
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Compounding Chemotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Cancer Type
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Compounding Chemotherapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Baxter International Inc.
• 15.3. Grifols SA
• 15.4. Comecer S.P.A.
• 15.5. Arxium Inc.
• 15.6. Dedalus Group
• 15.7. B. Braun Melsungen AG
• 15.8. Omnicell Technologies Inc.
• 15.9. The Metrix Company
• 15.10. Sterline S.R.L

16. Strategic Recommendations

17. About Us & Disclaimer